Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier

Translational Research

Volumn 166, Issue 4, 2015, Pages 384-398

  Sharma, Mukut ^a,b   Zhou, Jianping ^a   Gauchat, Jean François ^c   Sharma, Ram ^a   McCarthy, Ellen T ^b   Srivastava, Tarak ^a,d   Savin, Virginia J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARDIOTROPHIN LIKE CYTOKINE FACTOR 1; CYTOKINE; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR LIKE FACTOR 1; GLYCOPROTEIN GP 130; INTERLEUKIN 6; N,N DICYCLOPROPYL 4 [(1,5 DIMETHYL 1H PYRAZOL 3 YL)AMINO] 6 ETHYL 1,6 DIHYDRO 1 METHYLIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE 7 CARBOXAMIDE; PROTEIN INHIBITOR; STAT3 PROTEIN; STATTIC; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALBUMINOID; BLOCKING ANTIBODY; CARDIOTROPHIN-LIKE CYTOKINE; CYTOKINE-LIKE FACTOR-1; JANUS KINASE 2; PROTEIN KINASE INHIBITOR;

ADULT; ALBUMINURIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FOCAL GLOMERULOSCLEROSIS; GLOMERULAR FILTRATION BARRIER; GLOMERULUS; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; METABOLISM; PATHOLOGY; PERMEABILITY; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; SPRAGUE DAWLEY RAT;

ALBUMINS; ANIMALS; ANTIBODIES, BLOCKING; CYTOKINES; GLOMERULAR FILTRATION BARRIER; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; JANUS KINASE 2; KIDNEY GLOMERULUS; MALE; PERMEABILITY; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOKINE; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 84934983739     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.03.002     Document Type: Article

References (69)

1. J.K. Deegens, E.J. Steenbergen, and J.F. Wetzels Review on diagnosis and treatment of focal segmental glomerulosclerosis Neth J Med 66 2008 3 12
2. V.D. D'Agati, F.J. Kaskel, and R.J. Falk Focal segmental glomerulosclerosis N Engl J Med 365 2011 2398 2411
3. V.J. Savin, E.T. McCarthy, and M. Sharma Permeability factors in nephrotic syndrome and focal segmental glomerulosclerosis Kidney Res Clin Prac 31 2012 205 213
4. G. Lagrue, S. Xheneumont, A. Branellec, G. Hirbec, and B. Weil A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome Biomedicine 23 1975 37 40
5. W.W. Bakker, T. Borghuis, M.C. Harmsen, and et al. Protease activity of plasma hemopexin Kidney Int 68 2005 603 610
6. R. Lennon, A. Singh, G.I. Welsh, and et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes J Am Soc Nephrol 19 2008 2140 2149
7. L.C. Clement, C. Macé, C. Avila-Casado, and et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome Nat Med 20 2014 37 46
8. C. Wei, C.C. Moller, M.M. Altintas, and et al. Modification of kidney barrier function by the urokinase receptor Nat Med 14 2008 55 63
9. C. Wei, S. El Hindi, J. Li, and et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med 17 2011 952 960
10. J. Reiser, C.C. Nast, and N. Alachkar Permeability factors in focal and segmental glomerulosclerosis Adv Chronic Kidney Dis 21 2014 417 421
11. R.J. Maas, J.K. Deegens, and J.F. Wetzels Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 28 2013 1041 1048
12. J. Reiser, C. Wei, and J. Tumlin Soluble urokinase receptor and focal segmental glomerulosclerosis Curr Opin Nephrol Hypertens 21 2012 428 432
13. M. Sharma, R. Sharma, E.T. McCarthy, and V.J. Savin "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma J Am Soc Nephrol 10 1999 552 561
14. M. Sharma, R. Sharma, E.T. McCarthy, and V.J. Savin The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects Exp Biol Med 229 2004 85 98
15. V.J. Savin, M. Sharma, E.T. McCarthy, and et al. Cardiotrophin like cytokine-1: candidate for the focal glomerular sclerosis permeability factor J Am Soc Nephrol 19 2008 59A (F-FC-260)
16. Y. Shi, W. Wang, P.A. Yourey, and et al. Computational EST database analysis identifies a novel member of the neuropoietic cytokine family Biochem Biophys Res Commun 262 1999 132 138
17. G. Senaldi, B.C. Varnum, U. Sarmiento, and et al. Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family Proc Natl Acad Sci U S A 96 1999 11458 11463
18. G.C. Elson, E. Lelièvre, C. Guillet, and et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex Nat Neurosci 3 2000 867 872
19. H. Plun-Favreau, G. Elson, M. Chabbert, and et al. The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine EMBO J 20 2001 1692 1703
20. A. Uemura, T. Takizawa, W. Ochiai, M. Yanagisawa, K. Nakashima, and T. Taga Cardiotrophin-like cytokine induces astrocyte differentiation of fetal neuroepithelial cells via activation of STAT3 Cytokine 18 2002 1 7
21. G. Senaldi, M. Stolina, J. Guo, and et al. Regulatory effects of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function J Immunol 168 2002 5690 5698
22. K.M. Schmidt-Ott, J. Yang, X. Chen, and et al. Novel regulators of kidney development from the tips of the ureteric bud J Am Soc Nephrol 16 2005 1993 2002
23. K.M. Schmidt-Ott, D. Lan, B.J. Hirsh, and J. Barasch Dissecting stages of mesenchymal-to-epithelial conversion during kidney development Nephron Physiol 104 2006 56 60
24. F.C. Brosius 3rd New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy Rev Endocr Metab Disord 9 2008 245 254
25. V.J. Savin, R. Sharma, H.B. Lovell, and D.J. Welling Measurement of albumin reflection coefficient with isolated rat glomeruli J Am Soc Nephrol 3 1992 1260 1269
26. J. Bravo, and J.K. Heath Receptor recognition by gp130 cytokines EMBO J 19 2000 2399 2411
27. A.V. Purandare, T.M. McDevitt, H. Wan, and et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2 Leukemia 26 2012 280 288
28. J. Schust, B. Sperl, A. Hollis, T.U. Mayer, and T. Berg Stattic: a small-molecule inhibitor of STAT3 activation and dimerization Chem Biol 13 2006 1235 1242
29. R.J. Shalhoub Pathogenesis of lipoid nephrosis: a disorder of T-cell function Lancet 2 1974 556 560
30. P. Dall'Aglio, C. Chizzolini, and C. Brigati Minimal change glomerulonephritis and focal glomerulosclerosis markers and 'in vitro' activity of peripheral blood mononuclear cell Proc Eur Dial Transplant Assoc 19 1983 673 678
31. P. Dall'Aglio, P.L. Meroni, W. Barcellini, and et al. Altered expression of B lymphocyte surface immunoglobulins in minimal change nephrotic syndrome and focal glomerulosclerosis Nephron 37 1984 224 228
32. H. Yokoyama, H. Kida, T. Abe, Y. Koshino, M. Yoshimura, and N. Hattori Impaired immunoglobulin G production in minimal change nephrotic syndrome in adults Clin Exp Immunol 70 1987 110 115
33. J.M. Spinale, L.H. Mariani, and S. Kapoor A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease Kidney Int 87 2015 564 574
34. B.K. Meijers, and J. Reiser Reassessing the reassessment of suPAR in glomerular disease Front Med (Lausanne) 1 2015 59
35. J. Eugen-Olsen, O. Andersen, A. Linneberg, and et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population J Intern Med 268 2010 296 308
36. V.J. Savin, R. Sharma, M. Sharma, and et al. Circulating factor in recurrent focal segmental glomerularsclerosis N Engl J Med 334 1996 878 883
37. A.J. Dahly-Vernon, M. Sharma, E.T. McCarthy, and et al. Transforming growth factor-β, 20-HETE interaction, and glomerular injury in Dahl salt-sensitive rats Hypertension 45 2005 1 6
38. M. Sharma, R. Sharma, X.L. Ge, and et al. Early detection of radiation-induced glomerular injury by albumin permeability assay Radiat Res 155 2001 474 480
39. E.T. McCarthy, M. Sharma, and V.J. Savin Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis Clin J Am Soc Nephrol 5 2010 2115 2121
40. G.C. Elson, P. Graber, C. Losberger, and et al. Cytokine-like factor-1, a novel soluble protein, shares homology with members of the cytokine type I receptor family J Immunol 161 1998 1371 1379
41. S.S. Lesser, and D.C. Lo CNTF II, I presume? Nat Neurosci 3 2000 851 852
42. W.S. Alexander, S. Rakar, and L. Robb Suckling defect in mice lacking the soluble haemopoietin receptor NR6 Curr Biol 9 1999 605 608
43. N.G. Forger, D. Prevette, O. deLapeyrière, and et al. Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo J Neurosci 23 2003 8854 8858
44. E. Sohar, Y. Shoenfeld, R. Udassin, and A. Magazanik Cold-induced profuse sweating on back and chest. A new genetic entity? Lancet 2 1978 1073 1074
45. F. Rousseau, J.F. Gauchat, J.G. McLeod, and et al. Inactivation of cardiotrophin-like cytokine, a second ligand for ciliary neurotrophic factor receptor, leads to cold-induced sweating syndrome in a patient Proc Natl Acad Sci U S A 103 2006 10068 10073
46. L. Crisponi, G. Crisponi, A. Meloni, and et al. Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1 Am J Hum Genet 80 2007 971 981
47. S. Aljabari, E. Howard, T. Bell, and T.L. Vasylyeva Cold induced sweating syndrome with urinary system anomaly association Case Rep Pediatr 2013 2013 173890
48. P.C. Heinrich, I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway Biochem J 334 1998 297 314
49. R. Li, N. Yang, and L. Zhang Inhibition of Jak/STAT signaling ameliorates mice experimental nephrotic syndrome Am J Nephrol 27 2007 580 589
50. M.M. Seavey, and P. Dobrzanski The many faces of Janus kinase Biochem Pharmacol 83 2012 1136 1145
51. J.E. Darnell Jr. STATs and gene regulation Science 277 1997 1630 1635
52. H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
53. B.B. Aggarwal, A.B. Kunnumakkara, K.B. Harikumar, and et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci 1171 2009 59 76
54. G. He, and M. Karin NF-κB and STAT3: key players in liver inflammation and cancer Cell Res 21 2011 159 168
55. T. Decker, and P. Kovarik Serine phosphorylation of STATs Oncogene 19 2000 2628 2637
56. J. Wegrzyn, R. Potla, Y.J. Chwae, and et al. Function of mitochondrial Stat3 in cellular respiration Science 323 2009 793 797
57. D.J. Gough, A. Corlett, K. Schlessinger, and et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation Science 324 2009 1713 1716
58. N.C. Reich STAT3 revs up the powerhouse Sci Signal 2 2009 pe61
59. R. Liu, Y. Zhong, X. Li, and et al. Role of transcription factor acetylation in diabetic kidney disease Diabetes 63 2014 2440 2453
60. F. Pietrocola, V. Izzo, M. Niso-Santano, and et al. Regulation of autophagy by stress-responsive transcription factors Semin Cancer Biol 23 2013 310 322
61. J. Gong, A.R. Muñoz, D. Chan, and et al. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth Oncotarget 5 2014 2529 2541
62. L. Liu, K.M. McBride, and N.C. Reich STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3 Proc Natl Acad Sci U S A 102 2005 8150 8155
63. O.A. Timofeeva, S. Chasovskikh, I. Lonskaya, and et al. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA J Biol Chem 287 2012 14192 14200
64. D. Germain, and D.A. Frank Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy Clin Cancer Res 13 2007 5665 5669
65. P.B. Sehgal Paradigm shifts in the cell biology of STAT signaling Semin Cell Dev Biol 19 2008 329 340
66. Y. Dai, L. Gu, W. Yuan, and et al. Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis Kidney Int 84 2013 950 961
67. L. Gu, Y. Dai, J. Xu, and et al. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy AIDS 27 2013 1091 1098
68. R. Fagard, V. Metelev, I. Souissi, and F. Baran-Marszak STAT3 inhibitors for cancer therapy: have all roads been explored? JAKSTAT 2 2013 e22882
69. G. Miklossy, T.S. Hilliard, and J. Turkson Therapeutic modulators of STAT signalling for human diseases Nat Rev Drug Discov 12 2013 611 629